title: Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer?
authors.affiliation: Department of Hematology and Oncology, St. Louis University School of Medicine, Mo.
authors.forename: Sravanthi
authors.initials: S
authors.lastname: Ravulapati
authors.affiliation: Department of Internal Medicine, St. Louis University School of Medicine, Mo.
authors.forename: Cerena
authors.initials: C
authors.lastname: Leung
authors.affiliation: Department of Hematology and Oncology, St. Louis University School of Medicine, Mo.
authors.forename: Nishant
authors.initials: N
authors.lastname: Poddar
authors.affiliation: Department of Hematology and Oncology, St. Louis University School of Medicine, Mo. Electronic address: yifantu@slu.edu.
authors.forename: Yifan
authors.initials: Y
authors.lastname: Tu
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C582435:pembrolizumab